With the issue of data exclusivity for novel biologics re-emerging in the news, I’d like to present two arguments that […]
Biologic data exclusivity: The arguments for and against it Read Post »
I am honored to have been selected for the 2009 Kyoto Prize Journalism Fellowship, offered by Point Loma Nazarene University.
The October 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to
Journal of Commercial Biotechnology — October 2009 issue now available Read Post »
In these videos Pfizer’s Vice President and Global Head of Molecular Medicine, Aidan Power, talk about a future where everyone’s
In these videos Pfizer’s Vice President and Global Head of Molecular Medicine, Aidan Power, talk about a future where everyone’s
DCbiotech is a high-level networking group based in Washington DC. The objective is to bring together individuals working in, or
Introducing DCbiotech — High-level networking in the nation's capital Read Post »
DCbiotech is a high-level networking group based in Washington DC. The objective is to bring together individuals working in, or
Introducing DCbiotech — High-level networking in the nation’s capital Read Post »
With two life science IPOs earlier this month, and seemingly fewer stories of biotechnology firm liquidations, it seems that the
Biotechnology Industry Organization CEO Jim Greenwood appeared on CNBC’s SquawkBox defending the case for data exclusivity protection for novel biologic
Jim Greenwood on Data Exclusivity and Healthcare Innovation Read Post »
My most recent editorial in the Journal of Commercial Biotechnology, “The impact of the global financial crisis on biotechnology development,”
The impact of the global financial crisis on biotechnology development Read Post »
Get new actionable insights and updates from BiotechBlog
